STERIS plc (NYSE:STE) Shares Acquired by Assetmark Inc.

Assetmark Inc. increased its holdings in shares of STERIS plc (NYSE:STE) by 24.6% in the 3rd quarter, Holdings Channel.com reports. The firm owned 13,410 shares of the medical equipment provider’s stock after acquiring an additional 2,647 shares during the quarter. Assetmark Inc.’s holdings in STERIS were worth $3,252,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the business. J.Safra Asset Management Corp boosted its holdings in shares of STERIS by 77.9% in the 1st quarter. J.Safra Asset Management Corp now owns 121 shares of the medical equipment provider’s stock valued at $27,000 after buying an additional 53 shares in the last quarter. Central Pacific Bank Trust Division acquired a new position in STERIS in the third quarter valued at $28,000. Quent Capital LLC grew its holdings in shares of STERIS by 112.7% during the first quarter. Quent Capital LLC now owns 134 shares of the medical equipment provider’s stock worth $30,000 after purchasing an additional 71 shares during the last quarter. Headlands Technologies LLC acquired a new stake in shares of STERIS during the first quarter worth about $36,000. Finally, Versant Capital Management Inc lifted its holdings in shares of STERIS by 2,262.5% in the 2nd quarter. Versant Capital Management Inc now owns 189 shares of the medical equipment provider’s stock valued at $41,000 after purchasing an additional 181 shares during the last quarter. 94.69% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of brokerages have recently issued reports on STE. KeyCorp raised their target price on shares of STERIS from $255.00 to $265.00 and gave the stock an “overweight” rating in a research report on Tuesday, September 3rd. StockNews.com lowered STERIS from a “strong-buy” rating to a “buy” rating in a report on Tuesday, October 29th. JMP Securities reaffirmed a “market outperform” rating and set a $265.00 price objective on shares of STERIS in a research note on Wednesday, August 7th. Piper Sandler raised STERIS from a “neutral” rating to an “overweight” rating and boosted their target price for the company from $230.00 to $260.00 in a report on Thursday, October 24th. Finally, Needham & Company LLC reaffirmed a “hold” rating on shares of STERIS in a report on Friday, November 8th. Two investment analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to MarketBeat, STERIS presently has a consensus rating of “Moderate Buy” and a consensus target price of $253.00.

Insider Buying and Selling at STERIS

In other STERIS news, CFO Michael J. Tokich sold 23,332 shares of STERIS stock in a transaction that occurred on Tuesday, September 10th. The shares were sold at an average price of $247.00, for a total transaction of $5,763,004.00. Following the transaction, the chief financial officer now directly owns 42,930 shares of the company’s stock, valued at $10,603,710. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this hyperlink. 1.14% of the stock is owned by company insiders.

STERIS Price Performance

STE stock opened at $222.73 on Wednesday. The firm has a 50 day moving average of $231.90 and a 200-day moving average of $228.11. The company has a current ratio of 2.41, a quick ratio of 1.49 and a debt-to-equity ratio of 0.33. The company has a market cap of $21.96 billion, a price-to-earnings ratio of 50.85 and a beta of 0.85. STERIS plc has a 12-month low of $195.47 and a 12-month high of $248.24.

STERIS (NYSE:STE) last announced its quarterly earnings data on Wednesday, November 6th. The medical equipment provider reported $2.14 EPS for the quarter, beating analysts’ consensus estimates of $2.12 by $0.02. STERIS had a return on equity of 13.78% and a net margin of 8.02%. The business had revenue of $1.33 billion during the quarter, compared to the consensus estimate of $1.33 billion. During the same quarter in the previous year, the business earned $2.03 earnings per share. The business’s revenue for the quarter was up 7.3% on a year-over-year basis. As a group, equities analysts expect that STERIS plc will post 9.15 EPS for the current fiscal year.

STERIS Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, December 19th. Investors of record on Tuesday, November 19th will be issued a $0.57 dividend. This represents a $2.28 dividend on an annualized basis and a yield of 1.02%. The ex-dividend date of this dividend is Tuesday, November 19th. STERIS’s payout ratio is currently 52.05%.

STERIS Profile

STERIS plc provides infection prevention products and services worldwide. It operates through four segments: Healthcare, Applied Sterilization Technologies, Life Sciences, and Dental. The Healthcare segment offers cleaning chemistries and sterility assurance products; automated endoscope reprocessing system and tracking products; endoscopy accessories, washers, sterilizers, and other pieces of capital equipment for the operation of a sterile processing department; and equipment used directly in the operating room, including surgical tables, lights, and connectivity solutions, as well as equipment management services.